Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Serum C-reactive protein (CRP) level is frequently considered a prognostic predictor of immunotherapy. However, the prognostic role of the interim serum CRP levels before the third course of immunotherapy (CRP-C3) in patients with metastatic colorectal cancer (mCRC) receiving immunotherapy remains unclear.
Objectives: This study aimed to determine the predictive value of CRP-C3 for immunotherapy response and progression-free survival (PFS) and to compare its performance with other biomarkers, such as tumor mutational burden (TMB).
Design: We conducted a retrospective cohort study of 205 patients with mCRC who received immunotherapy.
Methods: Baseline CRP (CRP-B) and CRP-C3 levels were measured in this retrospective cohort study. Clinicopathological data were retrospectively analyzed using Cox regression analyses to identify independent predictive variables for immunotherapy response and PFS, then summarized in nomograms to predict prognosis.
Results: The median PFS periods were 8.47 months in the CRP-C3-low subgroup and 2.47 months in the CRP-C3-high subgroup ( < 0.001). The objective response rate (ORR) was 40.6% and 8.9%, respectively ( < 0.001). Although CRP-B failed in the multivariate Cox analysis, CRP-C3 performed exceptionally well, surpassing TMB levels (both < 0.001). Moreover, a prognostic model combining CRP-C3 and TMB levels could significantly stratify patients with mCRC receiving immunotherapy into low-, intermediate-, and high-risk subgroups ( < 0.001). Patients from different risk subgroups exhibited significantly different ORR (low- vs intermediate- vs high-risk groups: 59.2% vs 32.5% vs 0%, respectively, < 0.001) and Kaplan-Meier survival curves ( < 0.001).
Conclusion: This retrospective study indicates a potential association between decreased CRP-C3 levels and improved PFS in patients with mCRC receiving immunotherapy. The combination of CRP-C3 and TMB appeared to enhance predictive performance, suggesting their possible utility as prognostic indicators.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319200 | PMC |
| http://dx.doi.org/10.1177/17588359251356581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between medium-chain triglyceride intake and Functional Independence Measure-cognition score in adults following stroke: A retrospective cohort study.
JPEN J Parenter Enteral Nutr
September 2025
Center for Sarcopenia and Malnutrition Research, Kumamoto Rehabilitation Hospital, Kumamoto, Japan.
Background: Limited evidence exists regarding the cognitive and physical improvement effects of medium-chain triglyceride (MCT) intake in patients with stroke. This study aimed to investigate the association between MCT-enhanced rice consumption and enhancements in outcomes, including cognitive level, in patients following stroke.
Methods: We performed a retrospective cohort study on adults admitted to a rehabilitation center with cognitive decline following acute stroke.
Peripheral parenteral nutrition use outside of a dedicated nutrition support service: A descriptive cohort study.
JPEN J Parenter Enteral Nutr
September 2025
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia.
Background: Hospitalized patients may require nutrition support because of inadequate intake or impaired gut function. Enteral nutrition is preferred over parenteral nutrition because of fewer complications and earlier return of gut function. This study describes peripheral parenteral nutrition (PPN) use in an Australian tertiary center, evaluating its indications, incidence of adverse effects, and outcomes without the support of a nutrition support service.
View Article and Find Full Text PDFBackground: This retrospective analysis is a derivative cohort study based on a prior retrospective investigation by this author group.
Objective: To assess the effect of the number of cellular and/or tissue-based product (CTP) applications on healing outcomes and wound area reduction (WAR) rates in patients with chronic wounds of multiple etiologies.
Methods: Data from a multicenter private wound care practice electronic health record database were analyzed for Medicare patients receiving CTPs from January 2018 through December 2023.
Presentation of gastrointestinal bleeding in patients with antithrombotic therapy, results from a consecutive retrospective cohort.
Scand J Trauma Resusc Emerg Med
September 2025
Department of Clinical Sciences, Malmö, Section of Surgery, Lund University, Malmö, Sweden.
Background: Antithrombotic treatment might affect bleeding symptoms, identification of bleeding source and treatment for patients with acute gastrointestinal bleeding. This study aims to investigate possible differences in initial bleeding symptoms, identified bleeding site and treatment of patients with or without antithrombotic medication admitted for gastrointestinal bleeding.
Methods: All consecutive adult patients primarily admitted for gastrointestinal bleeding at Skane University Hospital between 2018-01-01 and 2019-06-31, were included in this study.
Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.
Breast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.